JoinClinicalTrials.com

• Metformin and Chemotherapy in Treating Patients With Stage III-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

  NCT02122185

  Conditions:   Brenner Tumor;   Malignant Ascites;   Malignant Pleural Effusion;   Ovarian Clear Cell Cystadenocarcinoma;   Ovarian Endometrioid Adenocarcinoma;   Ovarian Mixed Epithelial Carcinoma;   Ovarian Serous Cystadenocarcinoma;   Ovarian Undifferentiated Adenocarcinoma;   Recurrent Fallopian Tube Cancer;   Recurrent Ovarian Epithelial Cancer;   Recurrent Ovarian Germ Cell Tumor;   Recurrent Primary Peritoneal Cavity Cancer;   Stage IIIA Fallopian Tube Cancer;   Stage IIIA Ovarian Epithelial Cancer;   Stage IIIA Ovarian Germ Cell Tumor;   Stage IIIA Primary Peritoneal Cavity Cancer;   Stage IIIB Fallopian Tube Cancer;   Stage IIIB Ovarian Epithelial Cancer;   Stage IIIB Ovarian Germ Cell Tumor;   Stage IIIB Primary Peritoneal Cavity Cancer;   Stage IIIC Fallopian Tube Cancer;   Stage IIIC Ovarian Epithelial Cancer;   Stage IIIC Ovarian Germ Cell Tumor;   Stage IIIC Primary Peritoneal Cavity Cancer;   Stage IV Fallopian Tube Cancer;   Stage IV Ovarian Epithelial Cancer;   Stage IV Ovarian Germ Cell Tumor;   Stage IV Primary Peritoneal Cavity Cancer
  Interventions:   Drug: metformin hydrochloride;   Drug: placebo;   Drug: Chemotherapy
  Sponsor:   University of Chicago
  Recruiting
• MV-NIS Infected Mesenchymal Stem Cells in Treating Patients With Recurrent Ovarian Cancer

  NCT02068794

  Conditions:   Malignant Ovarian Brenner Tumor;   Ovarian Clear Cell Adenocarcinoma;   Ovarian Endometrioid Adenocarcinoma;   Ovarian Mucinous Adenocarcinoma;   Ovarian Seromucinous Carcinoma;   Ovarian Serous Adenocarcinoma;   Ovarian Transitional Cell Carcinoma;   Recurrent Ovarian Carcinoma;   Recurrent Primary Peritoneal Carcinoma;   Undifferentiated Ovarian Carcinoma
  Interventions:   Other: Laboratory Biomarker Analysis;   Procedure: Mesenchymal Stem Cell Transplantation;   Biological: Oncolytic Measles Virus Encoding Thyroidal Sodium Iodide Symporter
  Sponsors:   Mayo Clinic;   National Cancer Institute (NCI)
  Recruiting
• The Effects of Moderate Exercise on Distress, Quality of Life, and Biomarkers of Angiogenesis and Chronic Stress in Ovarian Cancer Survivors

  NCT03641287

  Conditions:   Ovarian Cancer;   Fallopian Tube Adenocarcinoma;   Fallopian Tube Carcinosarcoma;   Fallopian Tube Clear Cell Adenocarcinoma;   Fallopian Tube Endometrioid Adenocarcinoma;   Fallopian Tube Mucinous Adenocarcinoma;   Fallopian Tube Serous Adenocarcinoma;   Fallopian Tube Transitional Cell Carcinoma;   Fallopian Tube Undifferentiated Carcinoma;   Malignant Ovarian Brenner Tumor;   Ovarian Adenocarcinoma;   Ovarian Carcinosarcoma;   Ovarian Clear Cell Adenocarcinoma;   Ovarian Endometrioid Adenocarcinoma;   Ovarian Mucinous Adenocarcinoma;   Ovarian Seromucinous Carcinoma;   Ovarian Serous Adenocarcinoma;   Ovarian Transitional Cell Carcinoma;   Ovarian Undifferentiated Carcinoma;   Primary Peritoneal Serous Adenocarcinoma;   Primary Peritoneal Carcinosarcoma;   Primary Peritoneal Transitional Cell Carcinoma
  Interventions:   Other: Exercise Counseling;   Other: Aerobic Exercise;   Other: Physiological Support;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration;   Other: Best Practice
  Sponsors:   University of Washington;   National Cancer Institute (NCI)
  Recruiting
• Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

  NCT00719303

  Conditions:   Fallopian Tube Clear Cell Adenocarcinoma;   Fallopian Tube Endometrioid Adenocarcinoma;   Fallopian Tube Mucinous Adenocarcinoma;   Fallopian Tube Serous Adenocarcinoma;   Fallopian Tube Transitional Cell Carcinoma;   Malignant Ovarian Brenner Tumor;   Ovarian Clear Cell Adenocarcinoma;   Ovarian Endometrioid Adenocarcinoma;   Ovarian Mucinous Adenocarcinoma;   Ovarian Seromucinous Carcinoma;   Ovarian Serous Adenocarcinoma;   Ovarian Transitional Cell Carcinoma;   Primary Peritoneal Serous Adenocarcinoma;   Stage IIA Fallopian Tube Cancer AJCC v6 and v7;   Stage IIA Ovarian Cancer AJCC V6 and v7;   Stage IIB Fallopian Tube Cancer AJCC v6 and v7;   Stage IIB Ovarian Cancer AJCC v6 and v7;   Stage IIC Fallopian Tube Cancer AJCC v6 and v7;   Stage IIC Ovarian Cancer AJCC v6 and v7;   Stage IIIA Fallopian Tube Cancer AJCC v7;   Stage IIIA Ovarian Cancer AJCC v6 and v7;   Stage IIIA Primary Peritoneal Cancer AJCC v7;   Stage IIIB Fallopian Tube Cancer AJCC v7;   Stage IIIB Ovarian Cancer AJCC v6 and v7;   Stage IIIB Primary Peritoneal Cancer AJCC v7;   Stage IIIC Fallopian Tube Cancer AJCC v7;   Stage IIIC Ovarian Cancer AJCC v6 and v7;   Stage IIIC Primary Peritoneal Cancer AJCC v7;   Stage IV Fallopian Tube Cancer AJCC v6 and v7;   Stage IV Ovarian Cancer AJCC v6 and v7;   Stage IV Primary Peritoneal Cancer AJCC v7;   Undifferentiated Fallopian Tube Carcinoma;   Undifferentiated Ovarian Carcinoma
  Interventions:   Behavioral: Behavioral Dietary Intervention;   Behavioral: Compliance Monitoring;   Other: Counseling;   Other: Educational Intervention;   Behavioral: Exercise Intervention;   Other: Laboratory Biomarker Analysis;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration
  Sponsors:   Gynecologic Oncology Group;   National Cancer Institute (NCI)
  Recruiting